TSCAN THERAPEUTICS INC (TCRX) Stock News
NASDAQ:TCRX - Nasdaq - US89854M1018 - Common Stock
TCRX Latest News and Analysis
Why Is TScan Therapeutics Stock Gaining Today?
TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027.
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the...
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029...
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse...
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the...
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial...
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Upcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition Company to...
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and...
Oversold Conditions For TScan Therapeutics (TCRX)
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the...
Friday 9/27 Insider Buying Report: OBIO, TCRX
TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the...
TCRX Stock Earnings: TScan Therapeutics Meets EPS, Misses Revenue for Q2 2024
TCRX stock results show that TScan Therapeutics met analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
TCRX Stock Earnings: TScan Therapeutics Meets EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips TScan Therapeutics (NASDAQ:TCRX) just reported results for the second quarter o...
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity...
TScan Therapeutics Announces Updates to its Board of Directors
TScan Therapeutics Announces Updates to its Board of Directors
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as Chair;...
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
/CNW/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale...
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
/PRNewswire/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at...
TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024
TCRX stock results show that TScan Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.